

Granahan US Small Cap Discoveries UCITS

30 September 2022

Investment Summary

GIM's Discoveries Fund is a long-only U.S. equity strategy with a focus on small cap growth companies leveraging novel technologies to create products that address unmet needs in sizable markets. By performing in-depth fundamental research and analysis, we seek to uncover compelling growth opportunities with particular emphasis on innovation-driven sectors like life sciences and technology. Our PMs leverage the work of our sector specialists to build a portfolio of +/- 50 stocks with strong secular growth characteristics and acceptable valuations.

Fund Highlights

- We believe enterprise growth drives long-term stock appreciation and is derived from the creation of highly-coveted products and services.
- We clearly define our criteria for high-quality franchises and identify them through a repeatable investment process, including in areas that other growth managers may shun, such as small-cap biotech and other emerging growth sectors
- Changes in market sentiment provide opportunity to build positions in great companies, though we are not shy about trimming positions when valuations become decoupled from fundamentals.
- Each holding is classified by LifeCycle category – Core Growth, Pioneer, or Special Situation -- each with distinct performance drivers. LifeCycle diversification mitigates portfolio risk and allows us to focus on stock selection as the primary means to add value for our clients.

Portfolio Managers



Richard Watson, CFA 31 Yrs. Experience

Rich Watson is Senior Vice President and Portfolio Manager of Granahan Investment Management. His research expertise is in the biotechnology and life sciences sectors.



Jeffrey A. Harrison, CFA 24 Yrs. Experience


Jeff Harrison is Senior Vice President and Managing Director of Granahan Investment Management. He is a generalist with particular expertise in the healthcare, industrials, and financial services sectors.

About Granahan Investment Management

Founded in 1985, Granahan Investment Management, LLC is an employee-owned investment boutique specializing in smaller cap equity investments for large institutions and wealthy individuals. The firm utilizes fundamental, bottom-up research to uncover and invest in fast growing companies.

Annualized Performance

As of 30 September 2022



Inception Date: 06/30/2017

Calendar Year Performance

	YTD 2022	2021	2020	2019	2018	Since Inception Cumulative
US Small Cap Discoveries (Founders Class Acc USD)	-30.6%	3.6%	46.0%	26.5%	-4.7%	47.2%
Russell 2000 Growth	-29.3%	2.8%	34.6%	28.5%	-9.3%	26.7%

Inception Date: 06/30/2017

Fund Facts

Fund Assets:	\$31 Mil
Fund Launch Date:	30 June 2017
Asset Class:	US Equities
Market Cap:	\$100 Mil - \$3 Bil at purchase
Benchmark:	Russell 2000 Growth/Russell Microcap Growth
Structure:	UCITS
Domicile:	Ireland
UK Reporting Status:	Yes
Pricing:	Daily
Deal Cut Off:	1700 Dublin Time T-1
Year End:	31 December
Custodian & Admin:	RBC Investor & Treasury Svs. Ireland Ltd.
Website:	www.granahanfunds.com

Share Class Information

	US Small Cap Discoveries	
Founders Class Acc (USD)	IE00BZ3G1H34	GUSDFUA
Founders Class Acc (GBP)	IE00BDZ2QW58	GUSDFGA

Granahan Investment Management

404 Wyman Street, Suite 460
Waltham, MA 02451
Phone: 781-890-4412

Steve Sexeny

Senior Vice President
Business Development
ssexeny@granahan.com

Lori Azar

Assistant Vice President
Marketing Associate
lazar@granahan.com

Sector Diversification


Sector	Portfolio	Russell 2000 Growth
Basic Materials	2.6%	4.0%
Consumer Discretionary	9.5%	11.9%
Consumer Staples	2.1%	3.7%
Energy	1.1%	7.9%
Financials	4.4%	6.1%
Health Care	52.5%	24.6%
Industrials	8.9%	18.7%
Real Estate	1.6%	2.2%
Technology	13.2%	16.3%
Telecommunications	0.0%	2.3%
Utilities	2.6%	2.4%
[Cash]	1.4%	0.0%

Top 10 Positions

Security	LifeCycle Category	Percent of Portfolio
Revance Therapeutics Inc	Pioneer	3.0%
Kiniksa Pharmaceuticals Ltd.	Pioneer	2.8%
Kinsale Capital Group Inc	Core Growth	2.7%
Blueprint Medicines Corporation	Pioneer	2.6%
Casella Waste Systems, Inc.	Core Growth	2.6%
Materion Corp	Core Growth	2.6%
Portillo's Inc	Core Growth	2.6%
Shockwave Med Inc	Core Growth	2.6%
Arcus Biosciences Inc.	Pioneer	2.5%
Intellia Therapeutics Inc	Pioneer	2.5%
Total		26.5%

The securities identified and described do not represent all of the securities purchased, sold or recommended for client accounts. The reader should not assume that an investment in the securities identified was or will be profitable. A complete list of holdings is available upon request.

Growth of \$1,000



Characteristics

Characteristic	Portfolio	Russell 2000 Growth
Weighted Avg. Market Cap	\$2,182.2 mil	\$2,916.9 mil
Active Share	94.1%	-
Est 3-5 Yr EPS Growth	13.9%	9.8%
Forward P/E Ratio	18.6x	12.6x
LT Debt/Capital	29.3%	38.1%
Dividend Yield	0.4%	0.7%
Price to Book	2.8x	3.5x

Source: FactSet

Monthly Commentary

September was one of the worst months on record for Index returns, erasing most of the gains from the late June and July rally. The Russell 2000 Growth Index was down 9.0% and the Granahan US Small Cap Discoveries UCITS Fund was down 6.0%. Healthcare selection, particularly in biotechnology, and overweighting in this sector drove the outperformance. Industrials were the largest detractor this month. With biotechnology showing strength in the month, it makes sense that pioneers were the strongest lifecycle category with a positive return for the month. Core growth and special situations were both detractors. We continue to believe that the market leans towards growth stocks when inflation starts retreating, even if it is in the face of slowing growth, a recession and downward estimate revisions. Decelerating inflation is still likely to be the catalyst for the next move higher in the stock market and growth stocks. While we are not predicting how quickly this will occur, we continue to be positioned for this to happen in the future with a heavy concentration of core growth names in the portfolio.

Important Information for Investors

This material is directed at professional/sophisticated investors for their informational purposes only. It is not intended to be investment advice and does not constitute an offer to sell or solicitation to invest. Opinions contained herein reflect the judgment of GIM and are subject to change at any time. The Granahan US Focused Growth Fund, the Granahan US Small Cap Discoveries Fund and the Granahan US SMID Select Fund are sub-funds of the Granahan Funds plc (the "Company"), a public limited company (registered number 533587) authorized and regulated by the Central Bank of Ireland as an Undertaking for Collective Investment in Transferable Securities ("UCITS"). Authorization of the Company by the Central Bank of Ireland is not an endorsement or guarantee, nor is the Central Bank of Ireland responsible for the contents of any marketing material or the Company's offering documents. Shares of the Funds are only available for certain non-U.S. persons outside the United States and are restricted in certain jurisdictions. Any entity forwarding this material to other parties takes full responsibility for ensuring compliance with applicable securities laws in connection with its distribution.